I found that many people on Binance don't even understand what BIO is, but they are still discussing whether it will rise or fall. The structure of BIO is very complicated. If you go online to read its introduction, you will be dazzled by the various English terms such as BIO, molecule, and VitaDAO. It took me a long time to figure out the entire structure of BIO.

BIO is a scientific autonomous organization responsible for approving the establishment of subordinate ecological autonomous organizations, such as VitaDAO. Each autonomous organization has a research direction and reviews the research projects submitted. BIO and its subordinate ecological autonomous organizations have their own tokens for decentralized governance. Every project that passes the review and receives funding will mint its own IPNFT, which embeds the project progress data and various protocols, as well as the final patent certificate, and then tokenizes it in NFT. The technology of this IPNFT comes from molecule (molecular science), and the NFT token is also issued on the molecule platform.

The founders of BIO, molecule, and VitaDAO are actually one person, Paul Kohlhaas.

To make an analogy: BIO is the Chinese Academy of Sciences. VitaDAO and other seven autonomous organizations are research institutes under the Chinese Academy of Sciences, such as the Institute of Physics, the Institute of Biology, the Institute of Psychology, etc. Each project is a scientific research project established by the institute. IPNFT and tokens are the commercialization of research results. Buying tokens is equivalent to buying patents. However, in the BIO institute, the size of power does not depend on your official position, but on the number of tokens you own and pledge. The institute has BIO, and each institute also has its own tokens.

BIO's ideal is beautiful but the reality is very skinny. Research is a matter of luck. No matter how much investment is made, there may not be results, and even if there are results, it may not be commercialized. Therefore, BIO's profit prospects are very slim. But now the market value is already 2.6 billion, and the cost of early investors is less than one-tenth. I am not optimistic about its short-term market. $BIO

$